Objective: Several estimators exist when average utility scores are not available for patient populations with multiple disease conditions. The multiplicative estimator is a widespread choice among them. Our study is to empirically test the accuracy of the multiplicative estimator and compare it with other estimators. Methods: The Medical Expenditure Panel Survey (MEPS) has a nationally representative sample of the US civilian noninstitutionalized population. Using the pooled 2001 and 2003 data, a sample of 40,846 individuals with EQ-5D index scores were categorized into 238 disease condition categories. The study focus was the difference between the estimated and the observed mean scores for each comorbid pair, with the observed one presumed to be the true value. Results: The scores estimated by multiplying the 2 mean scores of the corresponding disease conditions on average had a statistically significantly larger difference (P Ͻ 0.0001) from the observed ones (Ϫ0.094) than simply picking the smaller mean of the 2 paired conditions (difference ϭ 0.025), the larger mean of the 2 (difference ϭ 0.071), the average of the 2 means (difference ϭ 0.048), or the mean of the condition with smaller sample size of the pair (difference ϭ 0.049). However, the multiplicative estimator performed better than the additive estimator (sum of the means minus 1, difference ϭ Ϫ0.123). Conclusions: Multiplication is not a good estimate when the average utility score for patients with 2 disease conditions is not readily available. The lower of the 2 utility scores had the least error among those estimators that we compared. Further research with an experimental design is warranted before a specific alternative can be firmly recommended.
U tility is a quantitative expression of an individual's preference for a particular state of health under the condition of uncertainty. 1 It is assessed on a scale where 0 represents a state of being dead, and 1 represents perfect health. One important usefulness of utility assessment arises from the ability to compute quality-adjusted survival, measured in quality-adjusted life years, 2 which has gained increasing attention from clinical investigators to evaluate the treatment outcomes in clinical trials and health economic evaluations. [3] [4] [5] Standard catalogs of utility scores have been developed, primarily for one disease condition, to facilitate the clinical decision analyses or treatment comparisons from a population perspective. 6, 7 The challenges arise when these off-the-shelf utilities are not readily available for those with multiple comorbid disease conditions. There is no standard method 8 to calculate the utility of comorbid disease conditions except by directly sampling from the population, which could be costly and time consuming. Given its appealing simplicity, a multiplicative model has usually been undertaken when utility scores for each disease condition of the comorbidities were available but not for the combined. 9, 10 For example, if the average utility scores for asthma and diabetes are 0.71 and 0.63, respectively, the average utility for individuals with both asthma and diabetes would be assigned as 0.71 ϫ 0.63 ϭ 0.45 based on the multiplicative model.
Flanagan et al 11 have examined the multiplicative model using the scores derived from Health Utility Index Mark 3 (HUI3) within a Canadian community population and their findings supported the use of multiplicative model. However, population-based scores are different by nations 12 as several countries have developed their own. [13] [14] [15] [16] [17] [18] [19] In addition, it is disturbing to observe in the Flanagan article that as large as 0.05 of an absolute difference is listed in tables between the observed utility from the sample and the estimated utility from the multiplicative model. 11 A clinical difference this large may be enough to change the preferred decision recommendation in a decision analysis, although such a difference might not be statistically significant.
Given the challenges in clinical decision analyses where utility scores are not available for patient populations with multiple comorbid disease conditions, our study was designed to empirically test the accuracy of the multiplicative estimator of utility scores in a US national representative community-dwelling population and compare the multiplicative estimator with several other estimators.
Methods

Data Source
The Medical Expenditure Panel Survey (MEPS) is a US nationally representative survey maintained by the Agency for Healthcare Research and Quality (AHRQ). The MEPS database provides national estimates of healthcare expenditures, sources of payment, and insurance coverage for the US civilian noninstitutionalized population. The MEPS uses an overlapping panel design in which data are collected through preliminary contact followed by a series of 5 rounds of interviews per panel with a time lag of 4 -5 months over a 2-year period.
The present study pooled the 2001 and 2003 MEPS data, so that no individuals coexist within the 2 separate panels. Our study focused on the self-administered paperand-pencil questionnaire portion of the MEPS, which was designed to collect a variety of health status and healthcare quality measures for all people aged 18 and older. A variable of person-level self-administered questionnaire weight was available from the MEPS data allowing estimates to be made for the community-dwelling US population after adjustment for questionnaire nonresponse.
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EQ-5D
We used the EQ-5D 21 preference-based index score to represent utility. The EQ-5D, which has been widely used throughout the world in both clinical investigations and health policy determinations, is a preference-based health status measure for global health related quality of life (HRQoL). It is one type of prescored multiattribute systems, which contains 5 attributes of the health status classification including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each attribute is measured by a question that has 3 possible responses-no problem, some problem, or severe problem. The combination of responses results in 243 (3 5 ) possible health states. Prior research developed a method for assigning a score between 0 and 1 to each of the 243 health states that represents an average preference for one state versus another in the UK population. 13 The EQ-5D has recently been weighted according to the social preferences of the US population. 19 This new scoring algorithm was used in our study for the US population, the significance of which has been stressed in the literature. 12, 22 As a generic and global HRQoL measure, the EQ-5D index score has a scale where 0 represents a state of being dead and 1 represents perfect health. There were 40,846 unique individuals of age 18 and above who have their EQ-5D questionnaires filled in the MEPS 2001 and 2003 data.
Disease Conditions
We used clinical classification categories (CCCs) defined in the MEPS to represent disease conditions. CCC was generated using the clinical classification software by AHRQ. 23 It aggregates the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) conditions and V-codes into 260 mutually exclusive clinically homogeneous categories. The MEPS does not provide the time duration for disease conditions. Thus, to better associate each disease condition with EQ-5D, which was administered within round 2 or 4 of the survey, only chronic disease conditions were included for the study purpose. 
Statistical Analysis
The multiplicative property of utilities, the preferencebased EQ-5D index scores in this case, was evaluated using the CCC comorbid pairs. First, the mean score for each individual disease condition was calculated from individuals excluding those with the other condition of the comorbid pair. Based on the multiplicative model, the "estimated" EQ-5D score for each comorbid pair was then calculated by multiplying the mean scores of each condition of the pair. The "observed" EQ-5D score of the comorbid pair was defined as the mean EQ-5D score among those individuals who had both specified conditions regardless of other conditions. The study focus is the difference and the mean square error (MSE) between the "observed" and the "estimated" EQ-5D index scores, with the "observed" one presumed to be the truth from the US population. The MSE is important because it performs better when measuring the accuracy of the estimation, whereas positive and negative differences may offset each other. The basic hypothesis is that an acceptable estimate is not significantly different from the observed value. The paired t test was used to evaluate this hypothesis. The concordance correlation coefficient 24 was also used to evaluate the agreement between the "estimated" and the "observed" scores. The concordance correlation coefficient is used, instead of the intraclass correlation coefficient, because it requires fewer assumptions than intraclass correlation coefficient based on analysis of variance. 25 An ordinary least square regression model was used, in addition, to test whether the estimated scores fit the observed ones well. The equation is:
where u 1,2 is the observed average score. û 1,2 is the multiplicative estimator achieved by u 1 ⅐ u 2 , the multiplication of the 2 average scores of the comorbid pair. The null hypothesis of the model is that the ␤ coefficient is not different from 1 and the constant term ␣ is not different from 0. If ␣ is fixed at 0, the ␤ coefficient is exactly the synergy coefficient of the multiplicative model referred to in the Flanagan et al article.
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is the error term of the equation. Meanwhile, 5 other estimators were calculated for comparison purposes: (1) The smaller mean of the 2 paired conditions; (2) the larger mean of the 2 paired conditions; (3) the average of the 2 means of the paired conditions; (4) the mean score of the condition with smaller sample size between the comorbid pair (ie, condition with more specific sample); (5) the additive estimator (sum of the 2 means of the paired conditions, then minus 1). 26 The same statistical analyses aforementioned were conducted for these 5 estimators as well.
We also applied a rescaling, or "purification" procedure as described in the Flanagan et al article 11 as a secondary analysis. In this case, the purified utility score is achieved by dividing all the utility scores aforementioned by the average utility of those individuals reporting no disease conditions, and the analysis is reconducted.
As a result of the MEPS sampling methods, health states with fewer than 100 observations do not maintain the
Utilities Should Not Be Multiplied US national representative property. 27 Thus, those comorbid pairs with less than 100 individuals observed were excluded from the analysis. This left us with 760 comorbid pairs in total. All scores aforementioned were adjusted using the self-administered questionnaire sampling weight in order for the study results to be representative of the communitydwelling US population.
Results
The average age of our sample was 45.2 years, and females comprised 51.8% of the total. The preference-based EQ-5D index score had a weighted average of 0.871 after adjustment for sampling, with the maximum value of 1 and the minimum value of Ϫ0.109 for 40,846 individuals of age 18 and above. The average EQ-5D score for those who had no disease condition reported was 0.952. Individuals reporting at least one chronic disease condition had an average score of 0.858. The average EQ-5D scores of each disease condition ranged from 0.501 to 0.985. Table 1 lists the average differences between the observed mean scores of the comorbid pairs and various estimators including the multiplicative estimator. The scores estimated by multiplying the mean scores of the corresponding conditions have a large difference from the observed scores on average (Ϫ0.094), which is statistically significantly smaller than zero ͓95% confidence interval (CI): Ϫ0.092, Ϫ0.096͔. Although there is no consensus on what constitutes a clinically important difference for the preference-based EQ-5D score, previous research has claimed different minimally important differences ranging from 0.033 to 0.07. 7,28 -30 The difference we found is clearly larger than this range. The multiplicative estimator also has a statistically significantly larger difference from the observed score (P Ͻ 0.0001) than the smaller mean of the 2 paired conditions (difference from the observed score ϭ 0.025), the larger mean of the 2 paired conditions (difference from the observed score ϭ 0.071), the average of the 2 means of the paired conditions (difference from the observed score ϭ 0.048), or the mean of the condition with smaller sample size between the pair, that is, more specific sample (difference from the observed score ϭ 0.049). However, the additive estimator has a larger difference from the observed score (Ϫ0.123) than the multiplicative estimator. The MSE basically provides the same evidence. For illustrative purpose, Table 2 shows the average observed EQ-5D, the score estimated by multiplication, and the difference for the 20 most prevalent comorbid pairs in the MEPS data. It is evident that the multiplicative estimator is quite different from the observed mean score. Table 1 also shows the results after applying the purification procedure. Although the multiplicative estimator has a smaller difference from the observed value compared with the unpurified results, this difference is still sizable (Ϫ0.043). The smaller mean remains the smallest for the difference between the estimated and the observed (0.027).
The concordance correlation coefficient, measuring the agreement between the estimated and the observed score, showed that the multiplicative estimator does not perform better than the smaller mean, the average of the means, or the mean of the condition with smaller sample size ( Table 3 ). The concordance correlation coefficient of the smaller mean (0.558) is significantly larger than those of all the other estimators (P Ͻ 0.0001). The regression model by Eq. 1 identified that the multiplicative estimator, as well as all other estimators, was significantly different from the observed score. The ␤ coefficient for the multiplicative estimator regression of 1.37 was statistically significantly different from 1 (95% CI: 1.32, 1.42), and the ␣ constant term Ϫ0.16 was statistically significantly different from 0 (95% CI: Ϫ0.19, Ϫ0.13). If the ␣ was forced to be zero in the model, the ␤ coefficient (synergy coefficient) is 1.138, still statistically significantly different from 1 (95% CI: 1.135, 1.141).
Both paired t tests and regression models showed that all these estimators have statistically significant differences from the observed score, implying that none of these estimators provide an unbiased estimate. However, it is obvious that the smaller mean of the 2 paired conditions performs the best among all estimators. It has the smallest difference from the observed score on average (actual difference ϭ 0.025 and MSE ϭ 0.0021), which is also smaller than the minimally important difference ranging from 0.033 to 0.07 in existing literature. 7,28 -30 The ␤ coefficient (synergy coefficient) from the ordinary least square regression is the closest to 1.0 (0.970) and the concordance correlation coefficient is the highest (0.558).
Discussion
It is challenging to assign an appropriate utility score for those individuals with multiple disease conditions when such a utility score is not readily available from the existing literature. Moreover, it is costly to measure utilities on subjects measuring all possible combinations of health states. This table is for a total of 760 comorbid pairs. The OLS models have the observed value as the dependent variable and the estimated value as the independent variable, where ␣ is the constant term of the model coefficient. The regressions were weighted by the number of individuals in each comorbid pair.
CCC indicates clinical classification category; CI, confidence interval.
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Using the preference-based EQ-5D index score, our study found that the estimator achieved by multiplication of the individual disease utilities is not a good choice based on a US national representative community-dwelling sample. Statistical notation can help to explain our results. Let U measure a person's utility. Let R 1 be having disease condition 1 (R 1 ϭ 1 if with disease 1, R 1 ϭ 0 if without), and R 2 be having disease condition 2 (R 2 ϭ 1 if with disease 2, R 2 ϭ 0 if without). Under multiplication, we make the assumption that:
where E represents the expectation. This seems to be a strong assumption. In reality, it is almost impossible for individuals to report all their comorbid disease conditions during a questionnaire survey, 31, 32 in part, because of recall bias 33, 34 and disease under-diagnosis. [35] [36] [37] Thus, even though a list of comorbid conditions are observed for certain individuals, that does not mean such a list is comprehensive and exhaustive. That is to say, when multiplying 2 utilities together, researchers are likely using utilities of patients with more than one comorbid condition, and comorbid conditions are likely correlated. So multiplying 2 utilities is double counting because not all patients have just one disease condition. This limits the application of utility multiplication in real-life decision analyses. In other words, there is no reason to expect the independence assumption inherent in Eq. 2.
The alternative estimators we tested for 2 disease conditions included those that generate utility scores either lower than the scores of the component conditions (the additive estimator) or higher (the rest). Among all the studied estimators, we recommend using the smaller mean of the individual disease utilities for comorbid conditions when utility of the pair is not available. For example, if the average utility scores for asthma and diabetes are 0.71 and 0.63, respectively, the recommended utility score assigned for individuals with both asthma and diabetes would be 0.63. We found this approach to have the smallest difference among all the estimators we investigated. We are, by no means, proposing the smaller mean as a best estimate. A good estimator should produce unbiased estimates. That is, the predicted values should not be systematically higher or lower than true values. Additionally, the concept of marginal disutility associated with each disease condition introduced by Sullivan et al is intuitively more attractive. 7, 38 Using regression modeling, marginal disutility of a certain disease is the utility difference between patients with that disease and those without after controlling for other covariates in the model. However, this approach can be sensitive to the appropriateness of the econometric modeling. Nevertheless, when the value of the marginal disutility for each disease condition is not readily available, the smaller mean is simple to apply as a second-best approach and is also empirically preferred to the multiplicative estimator based on a US national representative sample. Such a finding from our study is useful for both clinical investigators and those performing medical decision analyses or cost-effectiveness analyses because the multiplicative estimator has been so commonly used.
It is somewhat counter-intuitive that we found the minimum estimator to have less error than the more intuitive multiplicative estimator because the minimum estimator implies that patients feel only as bad as their worse condition. However, we are not trying to defend the theoretical justification of the minimum estimator, rather to provide empirical evidence showing that it is more accurate than the multiplicative estimator.
Flanagan et al 11 supported the multiplication of utilities for comorbid conditions using a Canadian community population. Their study differs from ours in some important ways. First, their study was conducted within a Canadian community population whereas ours used a US sample. As aforementioned, preference-based scores are different by nations, 12 and several countries have developed their own. [13] [14] [15] [16] [17] [18] [19] Second, Flanagan et al used HUI3, and we used the EQ-5D, the choice of which may influence decision-making. 39 The HUI uses a scoring formula that is a multiplicative multiattribute utility function. The EQ-5D uses econometric modeling. Although both are multiattribute systems, HUI uses the multiattribute utility theory, whereas EQ-5D does not. Additionally, we have to acknowledge that our study results may be sensitive to the preference scores chosen.
The Flanagan et al study 11 used rescaling, or "purification" as referred to in their article, by dividing the average utility score for cases reporting one or more conditions by the average utility of those reporting no disease conditions, the idea of which was similar to an article by Fryback et al a decade ago. 40 This step adjusted for health problems other than the disease conditions being studied such as loss of functional health attributable to unknown factors. A difficulty with rescaling (purification) is that it still needs to be estimated from the specified sample or population, which may not be readily available for clinical investigators or decision analysts. Nonetheless, our analysis was reconducted applying the purification procedure. The average difference between the multiplicative estimator and the observed value is still sizable (Ϫ0.043). The smaller mean remains the smallest for the difference between the estimated and the observed (0.027) with no overlapping of 95% CIs between the 2 estimators.
We also identified several ongoing research studies addressing our topic. [41] [42] [43] However, these studies are limited to a single disease condition and do not use a sample representative of the US population. Thus, our findings are more generalizable.
There are several methodological issues that need to be noted with respect to our study. First, the analysis was performed based on the US societal preference of EQ-5D, 19 which was at the population level. No utility prediction for a particular patient on the individual level is intended, and we recognize that the difference between these 2 has been clearly identified. 44, 45 Our study does not necessarily generalize to the context where holistic utilities are elicited from individuals, for example, using the time trade-off or standard gamble methods directly. Future research should examine this. Sec-
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Medical Care • Volume 46, Number 9, September 2008 ond, CCCs designed by AHRQ 23 were used to categorize disease conditions in our study. Although we could have grouped patients by the first 3 digits of the ICD-9 codes, the ICD-9 is more refined than CCC and thus has fewer individuals in each comorbid pair. Using the ICD-9 codes would have created many conditions with Ͻ100 individuals, which we felt to be undesirable. Conditions with Ͻ100 individuals lost the national representation property and were discouraged by MEPS. 27 Third, we did not assess the multiplicative characteristics of utility beyond 2 comorbid conditions due to limited sample size. However, with the finding that multiplication of 2 conditions is not a good estimate, we believe that the multiplication of more than 2 conditions will produce even more error. Fourth, no information was available from the data on the disease stage or severity, which could limit the accuracy of utility estimates for certain conditions. Fifth, we did not attempt to propose other estimators beyond the 6 we tested. A linear combination of these estimators represents other possible alternatives that require future study. Sixth, we did not isolate the effects of other disease conditions and demographic covariates when we examined the 2 index comorbidities. Although we could adjust for the number of other disease conditions and demographic covariates, this would require us to make statistical assumptions about how these other conditions and demographic covariates interact with the 2 index comorbidities.
Despite these limitations, this study makes an important contribution to the area of clinical decision analysis and cost-effectiveness analysis. We found that multiplication is not a good estimate whereas the lower utility of the 2 comorbid conditions is empirically preferred as a proxy for the combined health state. Further research with an experimental design is warranted before a specific alternative can be firmly recommended.
